Search

Displaying results 2871 - 2880 of 10000 in total
  1. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [L1118] It was never approved by the FDA. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

    Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MGProducts: Colprone Tab 5mg
  2. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    It was granted FDA approval on 29 September 2021. … with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022.

  3. Drug

    MK-1064

    go.drugbank.com/drugs/DB15028
    Investigational

    MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).

  4. Drug

    MK-6325

    go.drugbank.com/drugs/DB15249
    Investigational

    MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).

  5. Drug

    Velusetrag

    go.drugbank.com/drugs/DB12702
    Investigational

    It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance.

  6. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

    Synonyms: M6G
  7. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  8. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it

  9. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  10. Drug

    Alatrofloxacin

    go.drugbank.com/drugs/DB09335
    ApprovedWithdrawn

    It was withdrawn from the U.S. market in 2001.